Two new medications have been developed for fibromyalgia pain and diabetic nerve pain treatment by a company specializing in cannabis-based medicines. A Transdermal patch is placed on the skin and into the bloodstream for the medication of fibromyalgia pain and diabetic nerve pain.
The patch promotes healing to an injured area of the body. As compared to other types of medication delivery such as oral, topical, intravenous, intramuscular, etc, the transdermal
delivery flight path is more advantageous.
The patch used for the diabetic nerve pain treatment provides the patient with a controlled release of the medication into the patient, it can be provided to the patient via various forms such as:
- Through a porous membrane covering a reservoir of medication.
- Body heat melts thin layers of medication embedded in the adhesive which will be containing high potency cannabinoid (CBD) extract, this extract slowly enters the bloodstream and then penetrates the central nervous system of the patient delivering the pain relief sought.
- The CEO of cannabis science, Mr. Raymond C. Dabney believes that the future of cannabis science is based on the development of these two new pharmaceutical medicinal applications. The company is striving to enhance the land capacity for growth and facilities to manufacture its own products to supply scientists with proprietary materials to make these formulations. On the other hand cannabis company is also busy researching more potential needs for cannabis medical applications and introducing the methods for delivery of these medications.
CBD is the second major cannabinoid in marijuana after THC. Without the psychoactive effects that THC brings, it has anti-inflammatory and pain-reveling properties. MR Dabney also concludes that: ‘’ as more states nationwide legislate for the legalization of cannabis and cannabis-derived medications, here at Cannabis Science, the focus is on the development of pharmaceutical medications and applications to supply the huge growing demand expected over the coming few years.
New Treatments for Fibromyalgia (2026)
Learn more about our Stem Cell Treatment
Our treatment protocol is aimed at revolutionizing treatments for degenerative conditions
New treatments for fibromyalgia in 2026 include low-dose naltrexone (LDN), transcranial magnetic stimulation, updated pharmacological approaches, and emerging regenerative therapies including stem cell treatment. Research is increasingly targeting the neuroinflammatory mechanisms behind the condition. Here’s what’s available and what’s on the horizon.
New Treatments for Fibromyalgia
New treatments for fibromyalgia focus on symptom management and improving patient quality of life. Some of the complementary and alternative medicine (CAM) treatments that have shown promise include:
Mind-body techniques: These include biofeedback, hypnosis, and cognitive-behavioral therapy (CBT). Research data supports the use of these techniques, particularly when utilized as part of a multidisciplinary approach to treatment.
- Acupuncture: Although the data supporting the use of acupuncture for fibromyalgia is moderately strong, it can exacerbate symptoms for some patients, complicating its application for this condition.
- Manipulative therapies: Chiropractic and massage are examples of manipulative techniques, but the data supporting their use is relatively weak.
- Yoga, tai chi, and meditation: These complementary approaches have been included in comprehensive multidisciplinary treatment strategies for fibromyalgia.
- Pharmacological treatments: Pregabalin and duloxetine are two drugs approved by the United States Food and Drug Administration (FDA) for the management of fibromyalgia.
- Milnacipran: A dual norepinephrine and serotonin reuptake inhibitor, milnacipran has shown promise in the treatment of fibromyalgia. A double-blind, placebo-controlled trial demonstrated significant improvements in pain, patient’s global impression of change in their disease state, physical function, and fatigue when compared to placebo.
Stem Cell Therapy for Fibromyalgia
Stem cell therapy for fibromyalgia has not been well-established or widely studied. However, stem cell therapy has shown promise in treating various immune and inflammatory diseases, which could potentially be relevant to fibromyalgia.
Mesenchymal stem cell therapy (MSCT) has been used to treat autoimmune diseases, graft rejection, and inflammatory liver and pulmonary diseases, including COVID-19. The safety of MSCT has been largely demonstrated, but the efficacy for specific indications is still emerging.
Fibromyalgia Statistics
The prevalence of fibromyalgia varies depending on the population studied. In the general population, the prevalence of fibromyalgia is estimated to be between 2.9% and 4.7%. However, in specific populations, the prevalence can be higher. For example, among patients with ankylosing spondylitis, the prevalence of fibromyalgia ranges from 12.6% to 28.5%.
In another study, the prevalence of fibromyalgia among health care workers during the COVID-19 outbreak in Saudi Arabia was found to be 12.6% using the Fibromyalgia Rapid Screening Tool (FiRST) and 19.8% using the London Fibromyalgia Epidemiological Study Screening Questionnaire (LFESSQ).
- General Population: The prevalence is estimated to be an average of 3.8%, ranging between 2.9% and 4.7%.
- Patients with Ankylosing Spondylitis: The prevalence is notably higher, averaging at 20.55%, with a range from 12.6% to 28.5%.
- Healthcare Workers during the COVID-19 outbreak in Saudi Arabia: Two different screening tools were used. The Fibromyalgia Rapid Screening Tool (FiRST) showed a prevalence of 12.6%, while the London Fibromyalgia Epidemiological Study Screening Questionnaire (LFESSQ) indicated a prevalence of 19.8%.
Brief Overview of Fibromyalgia
Fibromyalgia is a complex chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. It affects approximately 2-8% of the global population, with a higher prevalence among women than men. The exact cause of fibromyalgia is still unknown, but it is believed to involve a combination of genetic, environmental, and psychological factors.
Symptoms and Diagnosis
The hallmark symptom of fibromyalgia is widespread pain that affects multiple areas of the body, including the muscles, joints, and tendons. Other common symptoms include fatigue, sleep disturbances, cognitive problems commonly referred to as “fibro fog,” headaches, and irritable bowel syndrome.
However, because fibromyalgia symptoms can vary greatly from person to person, diagnosis can be challenging.
To diagnose fibromyalgia, healthcare professionals typically rely on a combination of clinical observation and the presence of certain criteria. The most widely used diagnostic criteria are those established by the American College of Rheumatology (ACR) in 1990, which include widespread pain in at least 11 of 18 tender points for a minimum duration of three months. However, there has been a shift towards more holistic and patient-centered diagnostic approaches in recent years.
Prevalence and Impact
Fibromyalgia affects a significant number of individuals worldwide, with prevalence rates varying across different populations and regions. It is estimated that approximately 2-8% of the global population, or around 10 million people in the United States alone, are living with fibromyalgia.
The impact of fibromyalgia on individuals’ quality of life can be profound, often leading to decreased physical functioning, increased healthcare utilization, and significant psychological distress.
